Antiperspirants and cancer
This article was originally published in The Rose Sheet
Executive Summary
Use of antiperspirants or deodorants was not linked to an increased risk of breast cancer in a population-based case-control study published in the Oct. 16 Journal of the National Cancer Institute. Conducted by Dana Mirick, Fred Hutchinson Cancer Research Center, Seattle, et al., study involved 810 women diagnosed with breast cancer, 793 controls who were interviewed about antiperspirant and deodorant use following underarm hair removal. "To our knowledge," researchers state, "this is the only epidemiologic evidence pertaining to a possible association" between antiperspirants/deodorants and breast cancer and "our results provide no indication that such a relationship exists." Study prompted by "persistent" Internet rumors of a connection between the products and cancer...
You may also be interested in...
Unilever
Dove and Axe marketer unveils consumer Web site this month on antiperspirant safety in response to reports linking the products to breast cancer, firm says. Site, which can be accessed at 1www.antiperspirantsinfo.com or 2www.deodorantinfo.com, features expert opinions from physicians, frequently asked questions and links to further information. Internet rumors in 2002 raised concerns over antiperspirant safety, but a study published in the Journal of the National Cancer Institute the same year demonstrated no link between antiperspirants and cancer (3"The Rose Sheet" Oct. 21, 2002, In Brief)...
Methylparaben Accumulation Noted In UK Breast Tumor Study
Additional research, including studies measuring the levels of parabens in healthy breast tissue, is needed to evaluate the possible connection between the cosmetics preservatives and breast cancer, according to a British study published in the January issue of the Journal of Applied Toxicology
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.